These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1379 related articles for article (PubMed ID: 18421053)
1. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053 [TBL] [Abstract][Full Text] [Related]
2. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577 [TBL] [Abstract][Full Text] [Related]
3. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial. Tyagi P; Grothey A Clin Colorectal Cancer; 2006 Nov; 6(4):261-4. PubMed ID: 17241510 [TBL] [Abstract][Full Text] [Related]
4. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY; Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862 [TBL] [Abstract][Full Text] [Related]
5. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. Díaz-Rubio E; Tabernero J; Gómez-España A; Massutí B; Sastre J; Chaves M; Abad A; Carrato A; Queralt B; Reina JJ; Maurel J; González-Flores E; Aparicio J; Rivera F; Losa F; Aranda E; J Clin Oncol; 2007 Sep; 25(27):4224-30. PubMed ID: 17548839 [TBL] [Abstract][Full Text] [Related]
6. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965 [TBL] [Abstract][Full Text] [Related]
7. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ; J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840 [TBL] [Abstract][Full Text] [Related]
8. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Saltz LB; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Cassidy J J Clin Oncol; 2008 Apr; 26(12):2013-9. PubMed ID: 18421054 [TBL] [Abstract][Full Text] [Related]
9. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795 [TBL] [Abstract][Full Text] [Related]
10. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167 [TBL] [Abstract][Full Text] [Related]
11. XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis. Guo Y; Xiong BH; Zhang T; Cheng Y; Ma L Cancer Invest; 2016; 34(2):94-104. PubMed ID: 26864862 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin. Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749 [TBL] [Abstract][Full Text] [Related]
13. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Rittweger K; Gilberg F; Saltz L Br J Cancer; 2011 Jun; 105(1):58-64. PubMed ID: 21673685 [TBL] [Abstract][Full Text] [Related]
14. Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer. Vedat Bayoglu I; Yildiz I; Varol U; Cokmert S; Kucukzeybek Y; Alacacioglu A; Demir L; Dirican A; Akyol M; Yildiz Y; Oktay Tarhan M J BUON; 2015; 20(2):460-7. PubMed ID: 26011336 [TBL] [Abstract][Full Text] [Related]
15. Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). Maiello E; Di Maggio G; Cordio S; Cinieri S; Giuliani F; Pisconti S; Rinaldi A; Febbraro A; Latiano TP; Aieta M; Rossi A; Rizzi D; Di Maio M; Colucci G; Bordonaro R Clin Colorectal Cancer; 2020 Jun; 19(2):109-115. PubMed ID: 32089455 [TBL] [Abstract][Full Text] [Related]
16. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685 [TBL] [Abstract][Full Text] [Related]
17. A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer. Zhi J; Chen E; Major P; Burns I; Robinson B; McKendrick J; Rittweger K; Abt M; Goldstein D Cancer Chemother Pharmacol; 2011 Nov; 68(5):1199-206. PubMed ID: 21409383 [TBL] [Abstract][Full Text] [Related]
18. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911 [TBL] [Abstract][Full Text] [Related]
19. [Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)]. Sato A; Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Koizumi W; Mizunuma N; Takiuchi H Gan To Kagaku Ryoho; 2011 Apr; 38(4):561-9. PubMed ID: 21498982 [TBL] [Abstract][Full Text] [Related]
20. Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer. Moreno-Solórzano I; Ibeas-Rollan R; Monzó-Planella M; Moreno-Solórzano J; Martínez-Ródenas F; Pou-Sanchis E; Hernández-Borlan R; Navarro-Vigo M; Ortigosa-Rodríguez S; Gel-Moreno B Clin Colorectal Cancer; 2007 Sep; 6(9):634-40. PubMed ID: 17945035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]